Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Vanda Pharmaceuticals Inc., in its Q1 2024 results, showcased a mixed performance amidst its transition phase collaborating its existing products along with recent acquisitions.</li><li>The financial results reveal a decline in total revenues by 24% year-over-year to $47.5 million, primarily due to the impact of generic competition on its product HETLIOZ.</li><li>Despite this, there was a slight sequential increase in total revenues from the previous quarter, suggesting some stabilization in their financial outcomes.</li></ul>

Vanda Pharmaceuticals Inc., in its Q1 2024 results, showcased a mixed performance amidst its transition phase collaborating its existing products along with recent acquisitions.The financial results reveal a decline in total revenues by 24% year-over-year to $47.5 million, primarily due to the impact of generic competition on its product HETLIOZ.Despite this, there was a slight sequential increase in total revenues from the previous quarter, suggesting some stabilization in their financial outcomes.

Vanda Pharmaceuticals: Can It Attract Acquisition Interest After Future Pak's Offer Withdrawal? - Major Drivers

External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Key points (machine generated)<ul><li>Vanda Pharmaceuticals has established revenue-generating drugs and a pipeline of potential candidates in development.</li><li>The company has a strong balance sheet with ample cash reserves, offering potential for investments or acquisitions.</li><li>Despite these positive traits, the market values Vanda as if its core business is worthless, presenting a potential investment opportunity with significant upside potential.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Vanda Pharmaceuticals has established revenue-generating drugs and a pipeline of potential candidates in development.The company has a strong balance sheet with ample cash reserves, offering potential for investments or acquisitions.Despite these positive traits, the market values Vanda as if its core business is worthless, presenting a potential investment opportunity with significant upside potential.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Vanda Pharmaceuticals Inc. (VNDA) - Sunday, Oct 15, 2023

United States

Enanta Pharmaceuticals, Inc. manufactures pharmaceutical products. The Company develops, produces, and markets antibacterial drugs for hepatitis C virus, respiratory tract infections, intravenous, and oral treatments for hospitals and communities. Enanta Pharmaceuticals offers its products throughout the United States.

MacroGenics, Inc. develops novel biologics. The Company specializes in treatments for autoimmune disorders, cancer, and infectious diseases. MacroGenics serves the healthcare industry in the United States.

XOMA Corporation is a biotechnology royalty aggregator playing a unique role in helping biotech companies to improve human health. The Company focuses on acquiring economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates in return the seller receives non-dilutive and non-recourse funding to advance their internal drug candidates.

Concert Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company offers medicines and other related drug products. Concert Pharmaceuticals serves patients in the United States.

Esperion Therapeutics, Inc. develops and markets medical devices. The Company produces oral, small molecule therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol and other cardio metabolic risk factors.

Editas Medicine, Inc. offers transformative genome editing technology with the aim to translate the technology into a novel class of human therapeutics that enable precise and corrective molecular modification for the treatment of diseases. The Company operates in the United States.

Amarin Corporation PLC develops, manufactures, and distributes biopharmaceutical therapeutics. The Company markets its products used in the treatment of cardiovascular diseases to healthcare providers, clinics, researchers, and facilities throughout the world.

Akebia Therapeutics, Inc. manufactures biopharmaceutical products. The Company develop and distributes novel therapeutics based on the biology of hypoxia inducible factor (HIF) for patients with kidney diseases. Akebia Therapeutics serves customers in the United States.

MeiraGTx Holdings plc operates as a clinical stage gene therapy company. The Company offers a broad pipeline of preclinical and research programs, as well as provides gene therapy manufacturing and transformative gene regulation technology. MeiraGTx Holdings serves patients in the United States.

Merrimack Pharmaceuticals, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of drugs for the treatment of immunological and autoimmune diseases. Merrimack Pharmaceuticals serves patients in the United States.

Grandhope Biotech Company Limited develops, manufactures and markets regenerative medical materials and regenerative implantable medical devices.

Shanghai Kehua Bio-Engineering Co., Ltd. develops and manufactures bio-chemical reagents, medical equipment, diagnostic reagents, and genetic engineering pharmaceuticals.

Shanghai Kehua Bio Engineering (002022 CH)

Baotou Dongbao Bio-technology Company Limited develops, produces, sells gelatinrelated and small moledule collagen products. The Company also produces calcium hydrogen phosphate as a by-product.

Opthea Limited is a biologics drug developer for ophthalmic diseases. The Company develops therapies for diabetic macular edema, corneal neovascularization and transplantation, and dry eye disease. Opthea serves patients and healthcare providers in Australia.

PharmaEngine, Inc. operates as a biopharmaceutical company. The Company focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases.

TaiGen Biopharmaceuticals Holdings Limited is a research-based pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer research and diabetes-related complications.

Guangdong VTR Bio-tech Company Limited manufactures and sells feed additive, feed additive premix, veterinary medicine powder and granules. The Company's main product is Yiduozyme.

Adimmune Corp. is a human vaccine manufacturer. The company focuses on vaccines, diagnostics, and biological products. Adimmune manufactures vaccines such as the JEV, Tuberculin PPD, Tetanus toxoid, and influenza.

Monash IVF Group Ltd. is a fertility research and treatment center. The Company researches and develops reproduction supportive medications.

Mycenax Biotech Inc. develops and manufactures biopharmaceutical products derived from mammalian cell culture and microbial fermentation.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Vanda Pharmaceuticals (VNDA US)

Vanda Pharmaceuticals: Can It Attract Acquisition Interest After Future Pak's Offer Withdrawal? - Major Drivers

Vanda Pharmaceuticals Inc., in its Q1 2024 results, showcased a mixed performance amidst its transition phase collaborating its existing products...

Baptista Research

Vanda Pharmaceuticals Inc. (VNDA) - Sunday, Oct 15, 2023

Despite these positive traits, the market values Vanda as if its core business is worthless, presenting a potential investment opportunity with...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)